BIO-TECHNE Corp Share Price Nasdaq
Equities
US8783771004
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-22 | Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target | MT |
05-16 | Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing | MT |
Sales 2024 * | 1.16B 90.75B | Sales 2025 * | 1.25B 97.7B | Capitalization | 12.73B 997B |
---|---|---|---|---|---|
Net income 2024 * | 180M 14.09B | Net income 2025 * | 225M 17.62B | EV / Sales 2024 * | 11.1 x |
Net Debt 2024 * | 178M 13.91B | Net cash position 2025 * | 16.78M 1.31B | EV / Sales 2025 * | 10.2 x |
P/E ratio 2024 * |
72.2
x | P/E ratio 2025 * |
57.9
x | Employees | - |
Yield 2024 * |
0.4% | Yield 2025 * |
0.4% | Free-Float | 99.03% |
Latest transcript on BIO-TECHNE Corp
Managers | Title | Age | Since |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 29/04/18 |
James Hippel
DFI | Director of Finance/CFO | 53 | 31/03/14 |
Matthew McManus
COO | Chief Operating Officer | 55 | 01-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 31/12/02 | |
Randolph Steer
BRD | Director/Board Member | 74 | 31/12/89 |
Joseph Keegan
BRD | Director/Board Member | 71 | 25/10/17 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.15% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+24.10% | 12.11B | |
+27.41% | 12.07B | |
-8.12% | 11.19B |